NCI introduces client: Seqirus and their anti-viral therapy for influenza – Rapivab®
Rapivab® is indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 2 days.
The Seqirus Anti-Viral Therapy; Rapivab® is a single rapid IV administration that:
Reduces morbity and mortality in all patient populations
Provides rapid, effective and…